Johnson & Johnson (JNJ)
| Market Cap | 643.44B +51.6% |
| Revenue (ttm) | 97.93B +8.1% |
| Net Income | 21.04B -7.2% |
| EPS | 8.63 -7.6% |
| Shares Out | 2.41B |
| PE Ratio | 31.20 |
| Forward PE | 24.03 |
| Dividend | $5.36 (2.01%) |
| Ex-Dividend Date | Aug 25, 2026 |
| Volume | 3,242,190 |
| Open | 269.47 |
| Previous Close | 269.19 |
| Day's Range | 266.50 - 272.14 |
| 52-Week Range | 174.83 - 281.07 |
| Beta | 0.23 |
| Analysts | Buy |
| Price Target | 277.91 (+4.09%) |
| Earnings Date | Oct 13, 2026 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription... [Read more]
Financial Performance
In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price target is $277.91, which is an increase of 4.09% from the latest price.
News
Johnson & Johnson: Phase 3 MajesTEC-3 study shows ‘sustained’ disease control
Johnson & Johnson announced new data from the Phase 3 MajesTEC-3 study showing sustained disease control and survival with TECVAYLI plus DARZALEX FASPRO in patients with relapsed or refractory multipl...
New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma
Analysis shows ~87% of patients treated with TECVAYLI® plus DARZALEX FASPRO® as early as second line were estimated to have comparable mortality risk to the general population A separate analysis show...
J&J's Caplyta meets main goal of bipolar mania study
Johnson & Johnson said on Monday its experimental use of Caplyta for bipolar mania met the main goal of a late-stage study, bringing the drug a step closer to expanding beyond its currently approved...
Johnson & Johnson announces ‘positive’ results from Phase 3 trial of Caplyta
Johnson & Johnson announced positive topline results from the pivotal Phase 3 study evaluating Caplyta for the treatment of manic episodes with or without mixed features in adults with bipolar…
3 ‘Strong Buy’ Dividend Aristocrat Stocks to Generate Steady Cash
Johnson & Johnson ($JNJ), Chevron ($CVX), and Coca-Cola ($KO) are three dividend aristocrat stocks that investors seeking steady dividend payments can consider. These stocks are rated Strong Buys by a...
Johnson & Johnson Transcript: Deutsche Bank 2026 Healthcare Summit
The summit highlighted a focus on high-growth markets, robust innovation in oncology and immunology, and a diversified portfolio supporting double-digit growth targets. Med tech and pharma segments are positioned for margin improvement, with disciplined capital allocation and major legal risks resolved.
Johnson & Johnson announces new results from COPERNICUS study
Johnson & Johnson announced new results from the Phase 2b COPERNICUS study evaluating how subcutaneous Rybrevant Faspro plus Lazcluze, with less frequent dosing and prophylactic strategies, can improv...
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
Low rates of rash, blood clots and administration-related reactions were observed with subcutaneous treatment and prophylaxis Fewer than 1% of patients discontinued treatment due to treatment-related ...
Contineum, J&J's depression drug fails to meet mid-stage trial goal
Contineum Therapeutics said on Monday an experimental depression drug it developed with Johnson & Johnson failed to meet the main goal of a mid-stage study.
Johnson & Johnson Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The event highlighted a focused portfolio driving accelerated growth, robust pipeline progress, and strategic capital allocation. Advanced therapies in oncology and immunology, new product launches, and MedTech innovation underpin double-digit growth targets through the decade.
Johnson & Johnson reports PAPILLON study meets primary endpoint
Johnson & Johnson announced results from the final overall survival, or OS, analysis of the Phase 3 PAPILLON study evaluating first-line intravenous Rybrevant plus carboplatin-pemetrexed chemotherapy ...
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
RYBREVANT plus chemotherapy demonstrates durable benefit with a differentiated approach that dual-targets EGFR and MET Results mark significant progress for a patient population with poor outcomes and...
J&J Is In Talks to Sell Its Hips-and-Knees Business to Apollo for $20 Billion
The health-products company said it planned to hive off its DePuy Synthes unit to focus on higher-growth areas.
Apollo Global in talks to acquire J&J's orthopedics unit, Bloomberg News reports
Apollo Global Management is in discussions to acquire Johnson & Johnson's orthopedics unit in a deal that could value the unit at close to $20 billion, Bloomberg News reported on Friday, c...
Apollo Global in talks to buy J&J’s orthopedics unit, Bloomberg reports
Apollo Global Management (APO) is in talks to acquire the Johnson & Johnson (JNJ) orthopedics unit that the company has been looking to separate, Bloomberg’s Michelle Davis, Manuel Baigorri, and…
Johnson & Johnson receives CE Marking for ACUVUE OASYS MAX
Johnson & Johnson has received CE Marking for ACUVUE OASYS MAX 2-Week, a new reusable contact lens featuring proprietary MAX technologies designed to deliver superior comfort and visual clarity, even…
Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses
LIMERICK, Ireland--(BUSINESS WIRE)--Johnson & Johnson receives CE Marking for ACUVUE OASYS MAX 2-Week, a new reusable contact lens featuring proprietary MAX technologies.
Johnson & Johnson price target raised to $320 from $290 at HSBC
HSBC raised the firm’s price target on Johnson & Johnson to $320 from $290 and keeps a Buy rating on the shares. The firm adjusted targets in the healthcare group…
Johnson & Johnson Transcript: Wells Fargo 21st Annual Healthcare Conference
MedTech is on track for high-end growth, driven by a focused shift into cardiovascular, surgery, and vision, with robust innovation and a new operating model. Despite competitive and geopolitical headwinds, confidence remains high for 2026 and beyond, with major contributions expected from OTTAVA and portfolio optimization.
Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026
First presentation of pivotal Phase 3 CAPLYTA ® data in adults with bipolar mania underscores the asset's potential across mood disorders New SPRAVATO ® analyses and schizophrenia research emphasize a...
Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Deutsche Bank 2026 Healthcare Summit on Thursday, September 17th, 2026. Management will participate in a Firesid...
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 13th to review third-quarter results. Joaq...
China approves J&J's oral psoriasis pill, says drugmaker
China's drug regulator has approved Johnson & Johnson's oral pill for psoriasis, the company said on Thursday, intensifying competition in the world's second-largest pharmaceutical market with riva...
FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
IMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies while also preserving B-cell function Warm autoimmune hemolytic anemia is a rar...
US FDA expands approval for J&J's drug for rare blood disorder
The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's drug to treat a rare blood disorder, the company said on Monday.